Two companies are positioning for public-market scrutiny as investors hunt for the next wave of platform-driven biotech. Aspen Neuroscience and Bambusa Therapeutics have filed for IPOs, following a year in which cell and gene and immune-adjacent strategies have repeatedly drawn attention from both strategic and finance-led backers.